Efficacy Profiles: Brukinsa and Jaypirca in CLL

While the decision of which drug to use is best made on a case-by-case basis by a patient’s health care provider, reviewing the available clinical data on these two drugs will hopefully provide patients, their families, and their health care providers with a greater understanding of the potential benefits and uses of these two important drugs for the treatment of patients with CLL.